2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 638

The Progression of Brain MRI Biomarker of Cognitive Impairment (White Matter Hyperintensity) in Systemic Lupus: A Clinical and Imaging Longitudinal Study
Abstract Number: 1839

The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
Abstract Number: 2531

The Relapsing Polychondritis Disease Activity Index: International Development and Initial Validation of the First Disease Activity Score for Relapsing Polychondritis
Abstract Number: 1094

The Relationship Between Lumbar Spine Individual Radiographic Features and Low Back Symptoms with and without Associated Leg Symptoms: The Johnston County Osteoarthritis Project
Abstract Number: 1580

The Relationship Between Perceived Cognitive Dysfunction and Objective Neuropsychological Performance in Persons with Rheumatoid Arthritis
Abstract Number: 811

The Relationship Between Power Doppler Ultrasonography Outcomes and Clinical Efficacy in Abatacept-Treated Patients with Rheumatoid Arthritis and in Inadequate Response to Methotrexate
Abstract Number: 236

The Relationship Between Vibratory Sense and Somatosensory Pain Measures in Knee Osteoarthritis
Abstract Number: 780

The Relationship of Inflammation, Fatty Degeneration and the Effect of Long-Term TNF-Blocker Treatment On the Development of New Bone Formation in Patients with Ankylosing Spondylitis
Abstract Number: 184

The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Abstract Number: 2602

The Rheumatology Informatics System for Effectiveness (RISE): Enabling Data Access Across Disparate Sites for Quality Improvement and Research
Abstract Number: 1687

The Risk of Atrial Fibrillation in Patients with Rheumatoid Arthritis Compared to the General Population: A Large Cohort Study
Abstract Number: 849

The Risk of Cardiovascular Disease in Systemic Sclerosis: A Population-Based Cohort Study
Abstract Number: 2614

The Risk of Diabetes in Psoriatic Arthritis and Rheumatoid Arthritis
Abstract Number: 1593

The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Abstract Number: 2568

The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Giant Cell Arteritis: A Population-Based Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].